Ten science and technology research teams from across Australia pitched their innovations and ideas at the annual CSIRO ON Demo Night on April 19, where three annual awards were announced.
The teams, which were all part of the fourth cohort of the ON Accelerate Program – Australia’s national science and technology accelerator – powered by CSIRO, presented their ideas to industry, potential investors and stakeholders from across the country to accelerate their sci-tech research innovations and ideas towards success as ongoing ventures beyond the program.
Mary Webberly, part of the Noisy Guts Project team from the University of Western Australia, was recognised for her incredible achievements in science with the annual Breakout Female Scientist Award.
Her team, The Noisy Guts Project, are developing an acoustic belt that records gut noises over time to assist doctors with the accurate screening and diagnosis of gut disorders.
Steve Brodie, head of the ON Program said the Breakout Female Scientist award is presented to the female participant who has shown great leadership, resilience and a can do attitude in the commercialisation of important science.
Joss Kesby, one of three Diffuse Energy team members, was awarded a $30,000 scholarship by the Stanford Australia Foundation – CSIRO Scholarship, which recognises the individual who has displayed the most ‘entrepreneurial capacity’ in the ON Accelerate Program.
The Diffuse Energy team have developed a small wind turbine that, through being enclosed within a diffuser, can produce nearly twice the power output of existing wind turbines of the same size.
The third award winner of the night was Hyperdrive Science, which received the People’s Choice ‘Innovation IMPACT’ Award as voted by the audience.
Hyperdrive’s vision is to help pharmaceutical companies find cheaper, safer, and more effective drugs for everyone. To achieve this, they’ve developed a new way to beat the current costs and delays in drug development.
Hyperdrive Science is a new discovery platform that enables the rapid association between drugs and their targets in the human body, addressing this shortfall in the current drug development process.
The service increases the accuracy of drug candidate selection, reduces costs, and creates new opportunities for finding novel targets to unlock hidden value in the assets already owned by Hyperdrive’s customers.